CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 192 enrolled
Drug / intervention
N-acetyl cysteine +1 moredrug
Likely dose
N-acetyl cysteine 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03055377
NCT03055377Phase 3Completed
CompareCT.gov

N-Acetylcysteine for Youth Cannabis Use Disorder

Medical University of South Carolina·interventional·Posted Feb 16, 2017·Updated Dec 17, 2024

In Brief

A Phase 3 clinical trial evaluating N-acetyl cysteine and Placebo oral capsule for Cannabis Use Disorder. Completed, enrolled 192 participants across 1 site.

Detailed Summary

This is a 12-week randomized, placebo-controlled trial of N-acetylcysteine for cannabis use disorder (CUD) in youth (N=192). Participants will be randomized to double-blind NAC or PBO, yielding two equally-allocated treatment groups. All participants will receive brief weekly cannabis cessation counseling and medication management. The primary efficacy outcome will be the proportion of negative urine cannabinoid tests during the 12-week active treatment, compared between groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Use Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 16, 2017
Enrollment StartAug 3, 2017
Primary CompletionJan 31, 2024
Study CompletionFeb 26, 2024
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 9.4 years ago

Interventions

N-acetyl cysteinedrug

N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)

Placebo oral capsuledrug

Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)